Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
Pomerantz LLP has launched an investigation into EyePoint, Inc. (NASDAQ: EYPT) regarding potential securities fraud or unlawful business practices. The probe follows two significant clinical setbacks for the company's lead product candidate, DURAVYU™ (vorolanib intravitreal insert), intended to treat wet age-related macular degeneration (wet AMD). In August 2026, EyePoint reported that its LUGANO Phase 3 trial failed to meet visual acuity benchmarks against Regeneron Pharmaceuticals' Eylea, causing a nearly 67% drop in share price. A subsequent failure in the LUCIA Phase 3 trial in October 2026 led to an additional 85% collapse in stock value. Consequently, EyePoint has terminated its wet AMD clinical program and implemented a 53% workforce reduction to pivot toward diabetic macular edema programs.
Topics: class action lawsuit clinical trial failure layoffs securities fraud investigation stock price volatility
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures (9 articles)